About Biosynex
Biosynex is a company based in Strasbourg (France) founded in 2005. The company has 486 employees as of December 31, 2024. Biosynex has completed 8 acquisitions, including BigiX Pharma, Bixi Pharma and Chembio. Biosynex offers products and services including Rapid Diagnostic Tests, Ampliflash, and Ampliquick.
- Headquarter Strasbourg, France
- Employees 486 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Biosynex Sa
-
Annual Revenue
$105.11 M (USD)8.81as on Dec 31, 2024
-
Net Profit
-$45.02 M (USD)-17.28as on Dec 31, 2024
-
EBITDA
-$70.64 K (USD)99.41as on Dec 31, 2024
-
Latest Funding Round
$1.11 M (USD), Debt – Conventional
Jul 18, 2016
- Investors
-
Employee Count
486
as on Dec 31, 2024
-
Investments & Acquisitions
BigiX Pharma
& 7 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Biosynex
Biosynex is a publicly listed company on the EURONEXT with ticker symbol ALBIO in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Biosynex
Biosynex offers a comprehensive portfolio of products and services, including Rapid Diagnostic Tests, Ampliflash, and Ampliquick.
Tests for quick detection of medical conditions.
Device for molecular biology testing and analysis.
System for rapid PCR testing in healthcare settings.
People of Biosynex
Unlock access to complete
Funding Insights of Biosynex
- Total Funding Total Funding
- Total Rounds 2
- Last Round Debt – Conventional — $1.1M
-
First Round
First Round
(06 Nov 2015)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2016 | Amount | Debt – Conventional - Biosynex | Valuation |
investors |
|
| Nov, 2015 | Amount | Post-IPO - Biosynex | Valuation |
investors |
|
Investors in Biosynex
Biosynex has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bpifrance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate consultancy, advisory, and funding services are provided to businesses.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Biosynex
Biosynex has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include BigiX Pharma, Bixi Pharma and Chembio.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Digital remote health monitoring devices are provided to healthcare providers.
|
2019 | ||||
|
Point-of-care diagnostic devices for immunoassay tests are provided to clinicians.
|
2018 | ||||
|
Manufacturer of half cylinder cushion, antibacterial wedge & sanitizers
|
2017 |
Financial Statements - Biosynex
Biosynex Comparisons
Competitors of Biosynex
Frequently Asked Questions about Biosynex
Biosynex was founded in 2005 and raised its 1st funding round 10 years after it was founded.
Biosynex is headquartered in Strasbourg, France. It is registered at Strasbourg, Grand Est, France.
As of Dec 31, 2024, the latest employee count at Biosynex is 486.
Annual revenue of Biosynex is $105.11M as on Dec 31, 2024.
Biosynex (previously DIMA) is the manufacturer and provider of rapid membrane tests in the in-vitro diagnostic market. Its professional diagnostic products include Rapid diagnostic tests (RDTs) to detect an infection (HIV, malaria, mononucleosis, tonsillitis), an immune status (tetanus immunity), a physiological situation (pregnancy), an acute pathological situation (rupture of fetal membranes, myocardial infarction) or the presence of drugs in urine or saliva Blot tests (Western Blot or immunoblot) to indicate the presence or absence of antibodies and Real-time PCR (qPCR) enables the quantitative measure of DNA and ARN molecules. It also develops self-diagnostic tests for pregnancy, drug testing, blood pressure and glucose monitoring. It also provides oral care, reading glasses and foot care products.
Biosynex offers Rapid Diagnostic Tests, Ampliflash, and Ampliquick.
Yes, Biosynex is publicly traded on EURONEXT under the ticker symbol ALBIO.
Biosynex has made 8 acquisitions, including BigiX Pharma, Bixi Pharma, and Chembio.
Biosynex has 1 investor. Key investors include Bpifrance.
The ticker symbol of Biosynex is ALBIO on EURONEXT.